July 31, 2019
Astellas Pharma’s first-quarter sales ticked up 1.5% as the continued expansion of its prostate cancer treatment Xtandi (enzalutamide) and the overactive bladder (OAB) drug Betanis/Myrbetriq/Betmiga (mirabegron) made up for the negative impact of patent losses on major products. In the...read more